

In April 2018, Digital Diagnostics became the first company to receive FDA clearance for an AI diagnostic platform that makes a diagnosis without physician input at the point-of-care. Since then, Digital Diagnostics has diligently worked from within the healthcare system to establish autonomous diagnosis as the new standard of care, as supported by the American Diabetes Association.¹

The hard work has paid off as Digital Diagnostics' flagship product, LumineticsCore™ (formerly IDx-DR), an AI diagnostic system that autonomously diagnoses patients for diabetic retinopathy, is in use at over 20 health systems, including OSF Healthcare, a not-for-profit Catholic healthcare organization.

The partnership between Digital Diagnostics and OSF Healthcare has been the subject of several articles, blogs, videos, and podcasts in recent months, including [New AI Technology Helps Central Illinois Diabetics](#). Published on the *Fox Illinois* website, the article highlights patients' positive reactions to LumineticsCore in OSF doctors' offices.

"But had OSF not had that [LumineticsCore exam], I would have put that off a lot longer, like it's there, you know people should do it," said Huffman, an OSF patient.

The partnership between Digital Diagnostics and OSF Healthcare also made headlines, when *Vermillion County First* published [A New Vision for Diabetes-Related Eye Exams Coming to OSF in Champaign](#). In the article, Mark Meeker, DO, Vice President of Community Medicine at OSF HealthCare, discussed the partnership between Digital Diagnostics and OSF Healthcare and how LumineticsCore is changing the way diabetic retinopathy is diagnosed.

"We know from the pilot we launched through OSF Innovation at eight locations last May, that nearly one-quarter of all patients with diabetes who received the [LumineticsCore] exam tested positive for diabetic retinopathy," said Dr. Meeker. He further added, "There are interventions such as laser treatment and medication that can make a difference if an individual tests positive early enough, but prevention through better diabetes management is our goal."

The [Illinois Business Journal](#) highlighted the flourishing partnership between Digital Diagnostics and OSF Healthcare, calling attention to the fact that OSF Healthcare utilizes advanced technology for people with diabetes to get an exam to check for diabetic retinopathy when visiting their primary care provider. In the article, Dr. Meeker again explained the benefits of LumineticsCore.

"Early detection and prevention can prolong and even save vision," Dr. Meeker stressed.

OSF Healthcare also released an episode of its podcast, [Health Accelerated](#), during which, Dr. Meeker discussed in detail how OSF HealthCare is using Digital Diagnostics' flagship

product, LumineticsCore, to detect diabetic retinopathy, ultimately saving patients' sight, and, perhaps, their health.

"It's really a win-win-win all the way around," said Dr. Meeker.

Most recently, OSF Healthcare released a blog entitled "[Quick, Easy Eye Exam Helps Prevent Diabetic Retinopathy](#)." Throughout the blog, Dr. Meeker stressed the importance of making eye exams for diabetes as convenient as possible. He went on to explain how LumineticsCore makes in-office testing quick and easy, all while providing more accurate results than typical eye exams given in a primary care setting.

"The AI can see the early changes of diabetic retinopathy that we may not be able to see with our own eyes," Dr. Meeker said. He continued, "There's nothing as good as prevention. And the way you prevent it is to tightly control the diabetes to begin with. So as soon as we see those retinopathy changes, if we can really get the attention of the patient to really pay attention to their sugar control, we can decrease that progression through prevention, not just through treatment."

Through strategic collaborations, the vision of Digital Diagnostics continues to expand; however, the mission remains the same:

To benefit patients by transforming the accessibility, affordability, equity, and quality of global healthcare through the application of technology in the medical diagnosis and treatment process.

Note: Since the release of the above-mentioned publications, Digital Diagnostics rebranded its flagship product, IDx-DR, to LumineticsCore™. Any mention of the former product name, IDx-DR, in the linked content is in reference to LumineticsCore. The Indications for Use and autonomous AI technology behind [LumineticsCore](#)™ are unchanged.

References

1. ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Cusi, K., Das, S. R., Gibbons, C. H., Giurini, J. M., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Kosiborod, M., Leon, J., Lyons, S. K., & Murdock, L. (2022). Introduction and Methodology: *Standards of Care in Diabetes—2023*. *Diabetes Care*, 46(Supplement_1), S1–S4. <https://doi.org/10.2337/dc23-sint>